GEN Exclusives

More »

GEN News Highlights

More »
Nov 1, 2006

Shantha Biotechnics Consents to Manufacture Dengue Vaccine

  • Shantha Biotechnics will manufacture InViragen’s dengue vaccine candidate under an agreement between the two companies. This vaccine will be used to complete preclinical studies and initiate testing of its safety and efficacy in humans.

    The vaccine was designed by collaborators at the CDC to protect against all four of the dengue viruses. "InViragen and the CDC are using innovative recombinant technologies to create a novel vaccine," says Varaprasad Reddy, M.D., managing director of Shantha Biotechnics.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...
More »

Be sure to take the GEN Poll

Using Pet Dogs with Cancer in Preclinical Trials

Do you agree that pet dogs with cancer should be used in early cancer drug trials?

More »